Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Post-Mkt 03-24 17:17:08 EDT

95.52

-1.11

-1.15%

盘后96.20

+0.68+0.71%

17:03 EDT

High97.44	Low95.42	Vol1.53M
Open96.16	D1 Closing96.63	Amplitude2.09%
Mkt Cap18.93B	Tradable Cap17.10B	Total Shares198.17M
T/O146.76M	T/O Rate0.85%	Tradable Shares179.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":95.52,"timestamp":1774382400000,"preClose":96.63,"halted":0,"volume":1528780,"hourTrading":{"tag":"盘后","latestPrice":96.2,"preClose":95.52,"latestTime":"17:03 EDT","volume":27639,"amount":2640072.58137,"timestamp":1774386181842,"change":0.68,"changeRate":0.007119,"amplitude":0.012563},"delay":0,"changeRate":-0.011487115802545788,"floatShares":179000000,"shares":198173397,"eps":-5.95,"marketStatus":"Post-Mkt","change":-1.11,"latestTime":"03-24 17:17:08 EDT","open":96.16,"high":97.435,"low":95.42,"amount":146760647.9812,"amplitude":0.020853,"askPrice":97.38,"askSize":20,"bidPrice":95,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774396800000},"marketStatusCode":4,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":96.63,"preHourTrading":{"tag":"盘前","latestPrice":96.22,"preClose":96.63,"latestTime":"09:19 EDT","volume":156,"amount":14957.17002,"timestamp":1774358387296,"change":-0.41,"changeRate":-0.004243,"amplitude":0.000621},"postHourTrading":{"tag":"盘后","latestPrice":96.2,"preClose":95.52,"latestTime":"17:03 EDT","volume":27639,"amount":2640072.58137,"timestamp":1774386181842,"change":0.68,"changeRate":0.007119,"amplitude":0.012563},"volumeRatio":0.741242,"impliedVol":0.9945,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/RVMD/tweets","defaultTab":"tweets","newsList":[{"id":"2621750323","title":"A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2621750323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621750323?lang=en_us&edition=fundamental","pubTime":"2026-03-21 07:14","pubTimestamp":1774048450,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) recently announced that nine presentations covering clinical and preclinical data from its RAS(ON) inhibitor pipeline will be featured at the 2026 AACR Annual Meeting in San Diego.\nSee our latest analysis for Revolution Medicines.\nThe recent AACR news comes after a 21.6% 90 day share price return and a very large 3 year total shareholder return, suggesting momentum has been building around Revolution Medicines' RAS(ON) program despite short term share price...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/a-look-at-revolution-medicines-rvmd-valuation-after-aacr-ras","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/a-look-at-revolution-medicines-rvmd-valuation-after-aacr-ras","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1720051017.SGD","ON","BK4139","LU1861214812.USD","LU1854104046.USD","LU2298322129.HKD","LU1548497426.USD","LU2357305700.SGD","BK4141","LU1861215975.USD","RVMD","LU1978683503.SGD","LU1720051108.HKD","LU2360107325.USD","BK4588","IE00BFMHRM44.USD","BK4512","LU0124384867.USD","LU1861219969.SGD","LU0724618433.USD","LU1861220033.SGD","BK4585","IE00BD6J9T35.USD","IE00BZ199S13.USD","LU0348723411.USD","BK4605","LU1854103824.USD"],"gpt_icon":0},{"id":"2620724342","title":"Revolution Medicines General Counsel Jeff Cislini Disposes of USD 292000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620724342","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620724342?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:55","pubTimestamp":1773960923,"startTime":"0","endTime":"0","summary":"Jeff Cislini, General Counsel of Revolution Medicines, reported sales of common stock.He sold 1,795 shares on March 17, 2026 at USD 99.48 per share.He sold 1,163 shares on March 19, 2026 at USD 97.44 per share.Following the reported transactions, he beneficially owned 58,518 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4xRTf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines General Counsel Jeff Cislini Disposes of USD 292000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2620409537","title":"Revolution Medicines to present nine studies at the AACR annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620409537","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620409537?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:37","pubTimestamp":1773787059,"startTime":"0","endTime":"0","summary":"Revolution Medicines to present nine studies at the AACR annual meeting               Revolution Medicines said it will attend the AACR Annual Meeting in San Diego on April 17-22, 2026. The company is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4bfHNP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014021.USD","BK4588","BK4112","NDAQ","RVMD","SG9999014013.SGD","BK4139","SG9999014039.USD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4585","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2620401158","title":"Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401158","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401158?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:37","pubTimestamp":1773787020,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., March  17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257813/0/en/Revolution-Medicines-to-Showcase-Progress-Across-RAS-ON-Targeted-Oncology-Pipeline-with-Multiple-Presentations-at-the-2026-American-Association-for-Cancer-Research-AACR-Annual-Meet.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861215975.USD","BK4141","RVMD","LU2065732104.USD","BK4117","LU1861214812.USD","LU1854103824.USD","LU0124384867.USD","LU1720051108.HKD","BK4512","BK4585","LU1861219969.SGD","IE00BZ199S13.USD","IE00BD6J9T35.USD","AFG","LU2357305700.SGD","BK4107","IE00BFMHRM44.USD","LU2298322129.HKD","BK4139","PRGS","LU1854104046.USD","LU0348723411.USD","LU1978683503.SGD","BK4097","LU2360107325.USD","BK4605","LU1861220033.SGD","ON","LU1720051017.SGD","LU1548497426.USD","LU0724618433.USD"],"gpt_icon":0},{"id":"2620360495","title":"Revolution Medicines Coverage Assumed by Jefferies at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2620360495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620360495?lang=en_us&edition=fundamental","pubTime":"2026-03-17 02:42","pubTimestamp":1773686520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 14:42 ET (18:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2619145925","title":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2619145925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619145925?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:00","pubTimestamp":1773655210,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit TherapeuticsMarch 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-liste","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL4N4040QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXP","MUU","APA","TALO","ADBG","PSX","XOMX","INSM","RCL","CDRE","ALNY","BLDR","COGT","MPC","VLO","AAL","ADBE","AALG","ECL","AA","APEI","MU","ALG","BRBR","AROC","KYMR","MULL","RVMD","SCM","XOMO","CVX","PI","ABVX","MUD","FITB","PFSI","RPAY","BC","INCY","SMMT","XOMZ","KO","AXPG","XOM","CRC","AR","S","DSGN","RBRK"],"gpt_icon":1},{"id":"2619458101","title":"Revolution Medicines Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $140 VS $88","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619458101?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:18","pubTimestamp":1773649127,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4011AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2619523194","title":"Revolution Medicines (RVMD) Receives a Buy from Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2619523194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619523194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:59","pubTimestamp":1773403178,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Revolution Medicines, with a price target of $160.00. Schmid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-receives-a-buy-from-guggenheim-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-receives-a-buy-from-guggenheim-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2618625946","title":"Daraxonrasib Poised to Become Pancreatic Cancer Standard of Care on Strong RASolute 302 Outlook and Accelerated Launch Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625946","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625946?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:36","pubTimestamp":1773225370,"startTime":"0","endTime":"0","summary":"UBS analyst Michael Yee has maintained their bullish stance on RVMD stock, giving a Buy rating on March 9. Michael Yee has given his Buy rating due...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/daraxonrasib-poised-to-become-pancreatic-cancer-standard-of-care-on-strong-rasolute-302-outlook-and-accelerated-launch-path-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/daraxonrasib-poised-to-become-pancreatic-cancer-standard-of-care-on-strong-rasolute-302-outlook-and-accelerated-launch-path-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","RVMD","BK4124","BK4534","LU1863844749.USD","SMP","LU1863844665.USD","UBS","BK4118","LU3187612489.SGD","BK4139","IE0034235071.USD","LU1829250122.USD"],"gpt_icon":0},{"id":"2618621895","title":"Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621895?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:21","pubTimestamp":1773062464,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD – Research Report), Incyt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-revolution-medicines-rvmd-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-revolution-medicines-rvmd-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","HCSG","LU0029874061.USD","XLV","BK4581","RVMD","BK4588","LU0128526141.USD","INCY","LABU","XBI","BK4139","BK4550","BK4532","BK4585"],"gpt_icon":0},{"id":"2617541232","title":"Tango Therapeutics posts FY 2025 collaboration revenue of USD 62.4 million +108.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541232","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541232?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:01","pubTimestamp":1772712112,"startTime":"0","endTime":"0","summary":"Tango Therapeutics posts FY 2025 collaboration revenue of USD 62.4 million +108.2%               Tango Therapeutics posted a Q4 2025 net loss of USD 38.7 million, or USD 0.29 per share, and a FY 2025 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLb8fTRl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0320765992.SGD","LU0889565916.HKD","LU1037948541.HKD","BK4550","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU1066051498.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4532","LU2468319806.SGD","LU2087621335.USD","LU1934455277.USD","SG9999014013.SGD","LU1674673428.USD","LU0289739699.SGD","NDAQ","BK4566","LU2210149790.SGD","IE00B19Z3B42.SGD","LU2089984988.USD","RVMD","GILD","BK4568","IE00B19Z3581.USD","LU1585245621.USD","LU0965509101.SGD","SG9999015978.USD","ERAS","IE00BKVL7J92.USD","LU0965508806.USD","LU1778281490.HKD","TNGX","IE00B7SZLL34.SGD","LU1674673691.USD","SG9999015952.SGD","BK4578","LU2112291526.USD","LU0114720955.EUR","LU0965509283.SGD","IE00B3T34201.USD","LU0823416689.USD","LU2324357040.USD","BK4539","IE0002270589.USD","LU0861579265.USD","BK4585","BK4139","LU1023059063.AUD"],"gpt_icon":0},{"id":"2616304899","title":"Revolution Medicines CEO Mark A. Goldsmith Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616304899","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616304899?lang=en_us&edition=fundamental","pubTime":"2026-03-04 10:09","pubTimestamp":1772590198,"startTime":"0","endTime":"0","summary":"Mark A. Goldsmith, President and Chief Executive Officer of Revolution Medicines, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL6k0xjT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines CEO Mark A. Goldsmith Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2616398550","title":"Revolution Medicines Doubles Down on Costly RAS Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2616398550","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616398550?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:17","pubTimestamp":1772497066,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc. (($RVMD)) has held its Q4 earnings call. Read on for the main highlights of the call. Revolution Medicines’ latest earni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-doubles-down-on-costly-ras-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/revolution-medicines-doubles-down-on-costly-ras-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2614886909","title":"Revolution Medicines put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886909?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:55","pubTimestamp":1772218516,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Revolution Medicines (RVMD) with 3,163 puts trading, or 1.0x expected. Most active are Mar-26 90 puts and Mar-26 105 puts, wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2614886363","title":"Revolution's Daraxonrasib has 'Blockbuster' Potential, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2614886363","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614886363?lang=en_us&edition=fundamental","pubTime":"2026-02-28 00:23","pubTimestamp":1772209435,"startTime":"0","endTime":"0","summary":"Revolution Medicines'  daraxonrasib has \"blockbuster\" potential in the pancreatic ductal adenocarcinoma, or PDAC, market, UBS said in a Friday note.\"We think daraxonrasib has blockbuster potential in PDAC alone,\" the report said.The note said PDAC is a difficult market with few options for patients and where a novel overall survival-modifying treatment could have real impact and $6 billion to $7 billion sales potential.A key catalyst will be the readout of late-stage trial results of daraxonrasib in patients with second line metastatic disease in the first half of 2026, the report said.\"We see 70-80% PoS of a positive readout here for lead asset daraxonrasib,\" the note said. PoS refers to probability of success.UBS has a buy rating on the stock and a $145 price target.Price: 101.93, Change: -0.22, Percent Change: -0.22","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2614304518","title":"Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614304518","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614304518?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:56","pubTimestamp":1772193408,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $132.16, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"gpt_icon":0},{"id":"2614002089","title":"Tango Therapeutics weakness an ‘over reaction,’ says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2614002089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614002089?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:28","pubTimestamp":1772130483,"startTime":"0","endTime":"0","summary":"Stifel believes Tango Therapeutics (TNGX) shares are reacting in large part due to Revolution Medicines’ (RVMD) announcement of a clinical trial co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-weakness-an-over-reaction-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-weakness-an-over-reaction-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TNGX","BK4539","BK4007","RVMD","BK4127","SF","BK4139"],"gpt_icon":0},{"id":"2614429350","title":"Revolution Medicines Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2614429350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614429350?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:22","pubTimestamp":1772112120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 08:22 ET (13:22 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"gpt_icon":0},{"id":"2614042654","title":"Revolution Medicines (RVMD) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2614042654","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614042654?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:16","pubTimestamp":1772111772,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Revolution Medicines, with a price target of $147.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-wedbush-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2614041770","title":"Revolution Medicines price target raised to $115 from $109 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041770?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:52","pubTimestamp":1772110361,"startTime":"0","endTime":"0","summary":"BofA analyst Alex Stranahan raised the firm’s price target on Revolution Medicines (RVMD) to $115 from $109 and keeps a Buy rating on the shares. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-115-from-109-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-115-from-109-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":-0.0239},{"period":"1month","weight":-0.0511},{"period":"3month","weight":0.2038},{"period":"6month","weight":1.2193},{"period":"1year","weight":1.5356},{"period":"ytd","weight":0.2132}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.03269},{"month":4,"riseRate":0.666667,"avgChangeRate":0.052764},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.03349},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042659},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000709},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}